Talk:Ticagrelor

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Start‑class Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Start	This article has been given a rating which conflicts with the project-independent quality rating in the banner shell. Please resolve this conflict if possible.
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Ticagrelor.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

PLATO trial

"The controversy surrounding the PLATO trial of ticagrelor(Brilinta, AstraZeneca) " "According to the submission, he noted, 12 patients reported their own deaths by telephone." http://www.medscape.com/viewarticle/820236 — Preceding unsigned comment added by 89.132.124.186 (talk) 22:52, 9 February 2014 (UTC)[reply]

Immediately release tablet

formulation available in market 2409:40C1:10DA:6AE1:84AB:F67F:2903:3F15 (talk) 12:00, 29 January 2024 (UTC)[reply]